PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. million DNA bases. Muscles stop working.

Therapies 69

Therapies Immune Response DNA Virus 69

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. Florian S, Mitchison TJ. Chang, P. &

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

MAY 14, 2024

How do hydrophobicity, electrostatic charge, and secondary confirmation of helical polypeptides influence the stimulation of innate immune pathways in antigen-presenting cells (APCs)? Which natural agonists impede the activation of intracellular DNA sensors in APCs, and what challenges do they pose?

Engineering 59

Engineering Immune Response FDA Approval Clinical Trials 59

PLOS: DNA Science

OCTOBER 19, 2023

Last week DNA Science covered a setback in a clinical trial of a gene therapy for Duchenne muscular dystrophy (DMD). It aims to correct the faulty instructions at the DNA level, straightforward, at least conceptually, because mutations are deletions, of part or all of the gene. That’s not the case for ALS.

Therapies 107

Therapies FDA Clinical Trials Disease 107

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Immune Response Therapies Treatment 52

Drug Target Review

JUNE 9, 2023

Neoantigen-directed T-cell therapy is a potentially powerful approach that harnesses a patient’s own immune system to fight cancer. One aspect of the collaboration focuses on screening and identification of therapeutic T-cell receptors (TCRs) to target a common shared neoantigen present in many cancer patients.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Codon

DECEMBER 12, 2024

It’s important to note that the 300-page report, while presenting detailed evidence for the potential harms of mirrored life, uses painstakingly speculative language. DNA and RNA molecules are also built from exclusively right-handed nucleic acids. It gives humanity time to steer away. This is one of them.

RNA 104

RNA DNA Vaccine Virus 104

PerkinElmer

MAY 6, 2022

One approach currently being explored involves stimulating innate immune response pathways. For example, the STimulator of InterferoN Genes (STING) pathway, which is known to play a critical role in innate immunity in response to viral and bacterial DNA, has also been shown to promote anti-tumor immune responses.

Immune Response 52

Immune Response DNA Clinical Trials Engineering 52

Drug Target Review

SEPTEMBER 8, 2023

The cell’s nucleus, containing compacted DNA, is centrally positioned within the cell. It didn’t have the tools that are important for nuclear receptors, namely the ability to interact with DNA and the ability to translocate from the cytoplasm to the nucleus,” says Cheroutre.

Regulations 98

Regulations Research DNA Immune Response 98

Codon

SEPTEMBER 29, 2024

mRNA was the intermediate stage between DNA and protein, a dynamic entity that shifted depending on the second-to-second needs of the cell, able to point out if a cell was cancerous or stressed, what kind of cell it was, and so on. Collections of mRNA have been understood as a proxy for cell states for decades.

Engineering 142

Engineering Virus DNA Therapies 142

Codon

FEBRUARY 13, 2024

Such contaminants could have the same toxic effects as the bacterial infection, or provoke a severe immune response in the patient, and therefore the phage mixtures must go through extensive purification and testing procedures. This process would begin by taking a sample of bacteria from the patient and sequencing its DNA.

Therapies 131

Therapies Virus DNA Clinical Trials 131

Conversations in Drug Development Trends

JUNE 21, 2024

This year, Matt Cooper, PhD , our Executive Director, Therapeutic Strategy Lead, Oncology, attended and found the presentations around antibody-drug conjugates (ADCs) and tumor-infiltrating lymphocytes (TILs) to be of great interest to the future of oncology therapeutics.

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

Drug Target Review

APRIL 3, 2024

Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences.

Science 105

Science Clinical Development Treatment DNA 105

Drug Target Review

OCTOBER 2, 2024

While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. As with all CGTs, safety concerns, particularly related to immune responses and long-term effects, are crucial in cardiology. Allogeneic cell therapies must avoid immune rejection.

Therapies 98

Therapies Disease Engineering RNA 98

Drug Target Review

DECEMBER 13, 2024

These types differ in their etiology, natural history, and present distinct challenges in disease management. Combined with advances in antibody-drug conjugates (ADCs) and bi-specific antibodies (BsAbs), these developments present a promising opportunity to potentially enhance antitumor activity and survival outcomes for lung cancer patients.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

Drug Target Review

JANUARY 9, 2024

Presently, it is unknown how anthrobots encourage the growth of neurons, although the researchers confirmed that neurons grew under the area covered by a cluster of anthrobots, termed a “superbot.” He continued: “We’re now looking at how the healing mechanism works, and asking what else these constructs can do.”

Laboratories 59

Laboratories Immune Response DNA Science 59

Codon

JULY 27, 2023

They’ve just finished sequencing the patient’s genome, but they don’t have “DNA sorting” software. “The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. a lower risk of immune responses.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

They’ve just finished sequencing the patient’s genome, but they don’t have “DNA sorting” software. “The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. a lower risk of immune responses.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. The vaccine printer can make lots of different types of vaccines, including protein, DNA, and mRNA ones, but I’m sure this is all quite expensive right now. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. The vaccine printer can make lots of different types of vaccines, including protein, DNA, and mRNA ones, but I’m sure this is all quite expensive right now. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

LifeSciVC

MARCH 1, 2023

This was recently underscored by Nurix Therapeutics who presented multiple posters at the Society for Immunotherapy of Cancer Annual Meeting on their Phase One CBL-B program. And in early January, we bolstered the potential of CBL-B inhibition by announcing clearance of our first IND based on robust preclinical data.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

APRIL 7, 2023

The data will be presented at forthcoming medical meetings and shared with health authorities. Inhibition of PARP with Lynparza leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.

Trials 40

Trials DNA Treatment Therapies 40

The Pharma Data

DECEMBER 20, 2020

Pfizer and BioNTech announced additional data on neutralizing antibody and T-cell responses from their Phase I/II trial of their COVID-19 vaccine conducted in Germany. Biophytis presented preliminary analysis of its SARS-OBS trial evaluating the mobility, strength and physical activity of up to 100 sarcopenic patients.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

NOVEMBER 29, 2020

Compared to placebo, participants vaccinated with three HB-101 doses had: a 48 percent reduction in CMV viremia (presence of CMV DNA in the blood); a 42 percent reduction in the use of antiviral therapy; and. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

The Pharma Data

DECEMBER 27, 2020

Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. From these cells we apply proprietary methods to manufacture pure populations of only the cell types which we wish to use in patients.

Therapies 40

Therapies Clinical Trials Production Treatment 40

The Pharma Data

AUGUST 3, 2021

Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company’s business. 30% Non-GAAP guidance reflects adjustments presented in the earnings per share table above.

Production 52

Production Marketing Research DNA 52

Codon

APRIL 2, 2024

in physics at Princeton University, he had a remarkable idea: What if it were possible to build a circuit out of DNA, rather than electronics, and use it to “program” a living cell? Slides from a lab talk presented in Heidelberg, Germany in 1998. In 1997, as Michael Elowitz was studying for a Ph.D.

RNA 57

RNA Engineering Molecular Biology Synthetic Chemistry 57

Agency IQ

APRIL 12, 2024

For therapeutic protein products , a critical use of assays is the detection and assessment of potential anti-drug antibody (ADA) formation, signaling a product’s potential to induce an unwanted immune response. Additionally, six of these comments came from the same organization (Integrated DNA Technologies).

Production 40

Production FDA Therapies Biochemical Assays 40

Codon

APRIL 4, 2025

Today, six adjuvants have been approved by the Food and Drug Administration (FDA), each triggering a different kind of immune response. Some bacterial infections, like diphtheria or tetanus , cause disease using protein toxins, so the immune response must narrowly focus on neutralizing those protein targets.

Immune Response 85

Immune Response Vaccine Virus Disease 85

Codon

OCTOBER 27, 2024

Archaeologists have found evidence of ancient Egyptian mummies carrying the pathogen’s DNA , including some that had developed Pott’s disease — a bending of the spine brought on by TB spreading to bones. Interferon gamma release assays pick up an immune response to the infection. The current lineage of M.

Immune Response 94

Immune Response Doctors Disease Laboratories 94

New Drug Approvals

APRIL 4, 2025

For example, the present technology may relate to administering one or more mitochondrial-targeting peptidomimetics (alone, as formulated and/or in combination with other active pharmaceutical ingredients) in effective amounts to treat, prevent, inhibit, ameliorate or delay the onset of ophthalmic diseases, disorders or conditions (e.g.,

Disease 62

Disease Treatment Clinical Trials Therapies 62

Codon

APRIL 16, 2023

Skin microbes can trigger strong immune responses. These microbes were engineered to express tumor antigens that could “elicit T cells that were licensed by the commensal immune program but specific for a tumor,” including both CD4+ and CD8+ T cells, according to the study. coli DNA using a Retro-Cascorder.

Engineering 52

Engineering DNA RNA Science 52

Codon

APRIL 23, 2023

This newsletter’s format has shifted again, as I try to figure out the most enticing way to present this stuff. Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. 📎 Papers Strands of DNA can be used to build molecular logic gates.

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 23, 2023

This newsletter’s format has shifted again, as I try to figure out the most enticing way to present this stuff. Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. 📎 Papers Strands of DNA can be used to build molecular logic gates.

Vaccine 52

Vaccine DNA Virus Engineering 52